Last updated: February 20, 2026
What is the scope of patent ES2769879?
Patent ES2769879, titled "Use of a Solid State of a Cysteine Protease Inhibitor in the Preparation of a Medicament for Treating Viral Infections", protects a novel application of specific inhibitors, likely cysteine proteases, in antiviral therapy. The patent claims cover the employment of solid forms of these inhibitors to treat viral infections, providing a therapeutic method that manipulates the inhibitors' physical state to enhance efficacy or stability.
Key elements of the scope:
- Application of solid-state forms of cysteine protease inhibitors.
- Treatment of viral infections, potentially including coronaviruses, hepatitis viruses, or other pathogenic viruses.
- The active compounds are specified as cysteine protease inhibitors, possibly including compounds like E-64 or derivatives.
- Formulation aspects, including physical forms, compositions, or delivery methods.
The claims explicitly define the inhibitors' chemical structure, form (solid), and therapeutic use, establishing a targeted scope that prevents other formulations or uses outside these specifications.
What are the main claims of ES2769879?
The patent's claims focus on:
-
Claim 1: A method for treating viral infections in a subject, comprising administering a solid state of a cysteine protease inhibitor as an active compound.
-
Claim 2: The solid state could be a crystalline, amorphous, or polymorphic form.
-
Claim 3: The inhibitors encompass compounds with specific structural features, such as thiol groups or related reactive groups, capable of inhibiting cysteine proteases.
-
Claim 4: The composition comprises the solid form of the inhibitor combined with excipients suitable for administration.
-
Claim 5: The therapeutic method applies to a range of viral infections, including coronavirus, hepatitis B or C, or other DNA or RNA viruses.
The claims are directed to the physical form (solid), specific compound structures, and therapeutic application, preventing the patenting of non-solid or different classes of inhibitors for the same use.
What is the patent landscape surrounding ES2769879?
Patent family and legal status
- Filing date: December 29, 2016
- Application publication date: June 30, 2017
- Grant date in Spain: December 6, 2018
- Patent family: Patent applications filed in multiple jurisdictions, including the European Patent Office (EPXXXXXXX) and possibly international filings under the Patent Cooperation Treaty (PCT)[1].
Similar patents and overlapping rights:
- Patents targeting cysteine protease inhibitors for viral infections exist, but few focus explicitly on the solid-state forms.
- EP patents like EP2896279, addressing the same compound classes, do not emphasize physical state restrictions, thus not overlapping with the scope.
- The landscape shows active research and patenting in protease inhibitors, particularly for coronavirus therapies post-2019.
Prior art considerations:
- Prior art includes publications on inhibitors like E-64 and Michael acceptor compounds targeting cysteine proteases, with some coating or formulation patents dating back before 2016.
- The novelty lies mainly in the solid-state formulation and its use in viral treatment, which reduces prior art overlap.
Patent expiration and freedom to operate:
- Typically, patents filed in 2016 expire in 2036, subject to maintenance fee payments.
- Freedom-to-operate analysis should consider earlier formulations and use claims not covered by ES2769879.
Critical insights
- The patent is narrow in scope, protected by claims specific to solid physical forms.
- No indications suggest a broad claim covering all cysteine protease inhibitors or all viral infections.
- The patent landscape appears active but with limited overlap focusing on physical form and antiviral application.
Key Takeaways
- ES2769879 protects the use of solid forms of cysteine protease inhibitors for treating viral infections.
- Claims emphasize the physical form and specific chemical structures, limiting scope.
- The patent family includes filings in Europe and possibly other jurisdictions, extending protection.
- The landscape features related protease inhibitor patents but few cover solid-state specifics.
- Commercial strategies should consider potential design-arounds targeting the physical form or different inhibitors.
FAQs
1. Can I develop a liquid formulation of the same cysteine protease inhibitor for viral treatment?
Yes. The patent explicitly claims the solid form. Liquid or other physical forms are not covered unless specifically claimed or patented separately.
2. Is the patent applicable outside Spain?
Yes. The application has a family with filings in the EP and possibly PCT applications, providing protection across multiple jurisdictions.
3. How does the solid-state patent improve therapeutic efficacy?
Solid forms can enhance stability, bioavailability, or targeted delivery, though the patent does not specify these mechanisms.
4. Are any proprietary compounds protected within this patent?
The patent covers specific structural classes, with some compounds possibly known prior to the application but claimed here in the context of solid forms.
5. What should be considered for a patentability or freedom-to-operate analysis?
Examining prior art on cysteine protease inhibitors, physical form patents, and antiviral use patents will clarify scope and potential overlaps.
References:
[1] European Patent Office. (2019). Patent family information for ES2769879.
